What is the share price of Advanced Enzyme Technologies Ltd (ADVENZYMES) today?
The share price of ADVENZYMES as on 21st April 2025 is ₹301.75. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Advanced Enzyme Technologies Ltd (ADVENZYMES) share?
The past returns of Advanced Enzyme Technologies Ltd (ADVENZYMES) share are- Past 1 week: 4.08%
- Past 1 month: 1.06%
- Past 3 months: -11.12%
- Past 6 months: -34.12%
- Past 1 year: -20.55%
- Past 3 years: -2.54%
- Past 5 years: 103.20%
What are the peers or stocks similar to Advanced Enzyme Technologies Ltd (ADVENZYMES)?
The peers or stocks similar to Advanced Enzyme Technologies Ltd (ADVENZYMES) include:What is the dividend yield % of Advanced Enzyme Technologies Ltd (ADVENZYMES) share?
The current dividend yield of Advanced Enzyme Technologies Ltd (ADVENZYMES) is 1.69.What is the market cap of Advanced Enzyme Technologies Ltd (ADVENZYMES) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Advanced Enzyme Technologies Ltd (ADVENZYMES) is ₹3376.01 Cr as of 21st April 2025.What is the 52 week high and low of Advanced Enzyme Technologies Ltd (ADVENZYMES) share?
The 52-week high of Advanced Enzyme Technologies Ltd (ADVENZYMES) is ₹571 and the 52-week low is ₹257.90.What is the PE and PB ratio of Advanced Enzyme Technologies Ltd (ADVENZYMES) stock?
The P/E (price-to-earnings) ratio of Advanced Enzyme Technologies Ltd (ADVENZYMES) is 25.33. The P/B (price-to-book) ratio is 2.46.Which sector does Advanced Enzyme Technologies Ltd (ADVENZYMES) belong to?
Advanced Enzyme Technologies Ltd (ADVENZYMES) belongs to the Materials sector & Specialty Chemicals sub-sector.How to buy Advanced Enzyme Technologies Ltd (ADVENZYMES) shares?
You can directly buy Advanced Enzyme Technologies Ltd (ADVENZYMES) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Advanced Enzyme Technologies Ltd
ADVENZYMES Share Price
301.753.34% (+9.75)
ADVENZYMES Share Price Chart
High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
How to use scorecard? Learn more
ADVENZYMES Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 25.39 | 2.46 | 1.69% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 29.69 | 3.39 | 1.39% |
ADVENZYMES Analyst Ratings & Forecast
Detailed Forecast 0%
Analysts have suggested that investors can buy this stock
from 1 analyst
Price Upside
Earnings Growth
Rev. Growth
ADVENZYMES Company Profile
Advanced Enzyme Technologies is engaged in the research and development, manufacturing and marketing of over 400 products developed from over 60 indigenous enzymes.
Investor Presentation
View olderADVENZYMES Similar Stocks (Peers)
Compare with peersFLUOROCHEM
PE Ratio
100.38
1Y Return
7.13%
Buy Reco %
80.00
NAVINFLUOR
PE Ratio
77.25
1Y Return
28.53%
Buy Reco %
75.00
VINATIORGA
PE Ratio
53.60
1Y Return
1.85%
Buy Reco %
58.33
AKZOINDIA
PE Ratio
37.20
1Y Return
43.92%
Buy Reco %
50.00
AARTIIND
PE Ratio
36.70
1Y Return
41.45%
Buy Reco %
52.94
ADVENZYMES Forecasts
Price
Revenue
Earnings
ADVENZYMES Share Price Forecast
2024
Current
₹301.75
Baseline
Forecast for Feb 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2024
Current
₹301.75
Baseline
Forecast for Feb 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
ADVENZYMES Company Revenue Forecast
2024
Current
₹660.53
Baseline
Forecast for Mar 2025
High
₹—
Median
₹—
Low
₹—
All values in ₹ cr.
2024
Current
₹660.53
Baseline
Forecast for Mar 2025
High
₹—
Median
₹—
Low
₹—
All values in ₹ cr.
ADVENZYMES Stock EPS (Earnings Per Share) Forecast
2024
Current
₹11.92
Baseline
Forecast for Mar 2025
High
₹—
Median
₹—
Low
₹—
All values in ₹
2024
Current
₹11.92
Baseline
Forecast for Mar 2025
High
₹—
Median
₹—
Low
₹—
All values in ₹
ADVENZYMES
Income
Balance Sheet
Cash Flow
Annual Normal View
ADVENZYMES Income Statement
Annual Normal View
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 295.05 | 331.57 | 392.41 | 424.63 | 449.63 | 510.69 | 535.80 | 566.10 | 660.53 | 661.34 | ||||||||||
Raw Materials | 69.66 | 70.14 | 80.33 | 65.95 | 90.83 | 100.21 | 130.32 | 127.53 | 155.47 | 438.48 | ||||||||||
| Power & Fuel Cost | 10.17 | 12.87 | 18.10 | 19.29 | 19.37 | 21.45 | 29.95 | 38.10 | 40.92 | |||||||||||
| Employee Cost | 44.50 | 50.70 | 68.60 | 80.23 | 80.19 | 87.11 | 103.96 | 114.80 | 128.37 | |||||||||||
| Selling & Administrative Expenses | 23.50 | 25.61 | 38.41 | 40.04 | 37.58 | 37.72 | 51.80 | 56.22 | 60.11 | |||||||||||
| Operating & Other expenses | 12.47 | 18.00 | 20.64 | 30.84 | 12.65 | 22.78 | 10.77 | 50.56 | 48.48 | |||||||||||
EBITDA | 134.75 | 154.25 | 166.33 | 188.28 | 209.01 | 241.42 | 209.00 | 178.89 | 227.18 | 222.86 | ||||||||||
| Depreciation/Amortization | 8.72 | 12.76 | 18.30 | 21.12 | 25.78 | 28.72 | 34.98 | 35.03 | 35.24 | 35.76 | ||||||||||
| PBIT | 126.03 | 141.49 | 148.03 | 167.16 | 183.23 | 212.70 | 174.02 | 143.86 | 191.94 | 187.10 | ||||||||||
| Interest & Other Items | 7.86 | 4.43 | 9.06 | 5.20 | 4.08 | 2.57 | 2.96 | 3.48 | 4.12 | 3.59 | ||||||||||
| PBT | 118.17 | 137.06 | 138.97 | 161.96 | 179.15 | 210.13 | 171.06 | 140.38 | 187.82 | 183.51 | ||||||||||
| Taxes & Other Items | 42.34 | 45.51 | 48.91 | 50.90 | 49.87 | 64.21 | 51.48 | 34.75 | 54.52 | 50.56 | ||||||||||
| Net Income | 75.83 | 91.55 | 90.06 | 111.06 | 129.28 | 145.92 | 119.58 | 105.63 | 133.30 | 132.95 | ||||||||||
| EPS | 1.39 | 2.79 | 8.07 | 9.95 | 11.58 | 13.06 | 10.70 | 9.45 | 11.92 | 11.89 | ||||||||||
| DPS | 0.20 | 0.08 | 0.50 | 0.60 | 0.60 | 0.90 | 1.00 | 1.00 | 5.10 | 5.10 | ||||||||||
| Payout ratio | 0.14 | 0.03 | 0.06 | 0.06 | 0.05 | 0.07 | 0.09 | 0.11 | 0.43 | 0.43 |
ADVENZYMES Company Updates
FY 2016
Annual report
PDFFY 2017
Annual report
PDFFY 2018
Annual report
PDFFY 2019
Annual report
PDFFY 2020
Annual report
PDFFY 2021
Annual report
PDFFY 2025
Investor Presentation
Feb 8PDF
Nov 9PDF
ADVENZYMES Past Performance & Peer Comparison
Comparing 3 stocks from
MaterialsSpecialty Chemicals
Compare valuation on Screener
MaterialsSpecialty Chemicals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Advanced Enzyme Technologies Ltd | 25.33 | 2.46 | 1.69% |
| Gujarat Fluorochemicals Ltd | 100.38 | 7.35 | 0.08% |
| Navin Fluorine International Ltd | 77.25 | 8.77 | 0.36% |
| Vinati Organics Ltd | 53.60 | 7.03 | 0.42% |
ADVENZYMES Stock Price Comparison
Compare ADVENZYMES with any stock or ETFCompare ADVENZYMES with any stock or ETF
ADVENZYMES
ADVENZYMES Shareholdings
ADVENZYMES Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
ADVENZYMES Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
ADVENZYMES Shareholding Pattern
ADVENZYMES Shareholding History
Foreign Institutions
Mutual Funds Invested in ADVENZYMES
A list of mutual funds holding the stock, ranked on the basis of Market-cap held which is calculated as the value of stock held in the portfolio divided by its market cap
Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Advanced Enzyme Technologies Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 2.0824% | Percentage of the fund’s portfolio invested in the stock 1.43% | Change in the portfolio weight of the stock over the last 3 months 1.43% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 24/51 (+18) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.8278% | Percentage of the fund’s portfolio invested in the stock 1.06% | Change in the portfolio weight of the stock over the last 3 months -0.13% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 38/59 (-9) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.7218% | Percentage of the fund’s portfolio invested in the stock 1.71% | Change in the portfolio weight of the stock over the last 3 months -0.31% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 18/55 (-3) |
Compare 3-month MF holding change on Screener
smallcases containing ADVENZYMES stock
Looks like this stock is not in any smallcase yet.
ADVENZYMES Events
ADVENZYMES Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
ADVENZYMES has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 1.69%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹16.89 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
ADVENZYMES Upcoming Dividends
No upcoming dividends are available
ADVENZYMES Past Dividends
Cash Dividend
Ex DateEx DateJul 18, 2024
Final
Final | Div/Share: ₹1.10
Dividend/Share
₹1.10
Ex DateEx Date
Jul 18, 2024
Cash Dividend
Ex DateEx DateMay 17, 2024
Interim
Interim | Div/Share: ₹4.00
Dividend/Share
₹4.00
Ex DateEx Date
May 17, 2024
Cash Dividend
Ex DateEx DateAug 4, 2023
Final
Final | Div/Share: ₹1.00
Dividend/Share
₹1.00
Ex DateEx Date
Aug 4, 2023
Cash Dividend
Ex DateEx DateMay 19, 2023
Interim
Interim | Div/Share: ₹4.00
Dividend/Share
₹4.00
Ex DateEx Date
May 19, 2023
Cash Dividend
Ex DateEx DateAug 11, 2022
Final
Final | Div/Share: ₹1.00
Dividend/Share
₹1.00
Ex DateEx Date
Aug 11, 2022
ADVENZYMES Stock News & Opinions
Articles & Videos
Corporate
Advanced Enzyme Technologies allots 500 equity shares under ESOS
Advanced Enzyme Technologies has allotted 500 equity shares under ESOS on 19 March 2025. Consequent to the said allotment, the paid-up share capital of the Company stands increased from Rs 22,37,61,300 comprising of 11,18,80,650 equity shares of Rs 2 each to Rs 22,37,62,300 comprising of 11,18,81,150 equity shares of Rs 2 each. Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Advanced Enzyme Technologies consolidated net profit declines 9.86% in the December 2024 quarter
Net profit of Advanced Enzyme Technologies declined 9.86% to Rs 37.65 crore in the quarter ended December 2024 as against Rs 41.77 crore during the previous quarter ended December 2023. Sales rose 5.08% to Rs 169.11 crore in the quarter ended December 2024 as against Rs 160.94 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales169.11160.94 5 OPM %32.6733.40 - PBDT61.9967.48 -8 PBT53.0258.88 -10 NP37.6541.77 -10 Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Advanced Enzyme Techs. to announce Quarterly Result
Advanced Enzyme Techs. will hold a meeting of the Board of Directors of the Company on 8 February 2025.Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Advanced Enzymes announces incorporation of new entity in California for laboratory testing services
The Board of Directors of Advanced Enzymes USA (AEU), a wholly owned subsidiary of Advanced Enzyme Technologies has accorded its approval for formation of a new corporation in California (US) to be named as Starya Labs, Inc (Starya Labs). In view of this, Starya Labs will be a step down wholly owned subsidiary of Advanced Enzyme Technologies. Cal-India Foods International USA (SEB), a step-down wholly owned subsidiary of Advanced Enzyme Technologies and wholly owned subsidiairy of AEU to spin-off and transfer its enzyme/probiotic laboratory testing services (SEB Lab) together with certain assets and liabilities related to the said SEB Lab into Starya Labs. The said new corporation, Starya Labs will be a wholly owned subsidiary of AEU. Powered by Capital Market - Live
4 months agoCapital Market - Live
Spotlight
Advanced Enzyme Tech drops after PAT slides 5% YoY in Q2 FY25
The revenue de-grew by 3% in Americas, 27% in Europe, 9% in Asia (ex-India) while it grew by 8% in rest of the world. On the segmental front, the revenue from human nutrition segment declined by 2% YoY to Rs 99.2 crore while animal nutrition income grew by 6% YoY to Rs 18.1 crore in second quarter of FY25. The bio-processing segment revenue slipped 33% to Rs 16.8 crore while specialized manufacturing segment rose 9% to Rs 12 crore in September 2024 quarter over September 2023 quarter. The domestic sales constituted about 48% of revenue from operations during Q2 FY25 as compared to 52% during Q2 FY24. International sales were 52% of revenue from operations during Q2 FY25 as compared to 48% during same quarter last year. EBITDA de-grew by 17% YoY to Rs 42.4 crore in the second quarter. EBITDA margin was 29% and PAT margin stood at 23% during the quarter. Profit before tax was at Rs 42.21 crore during Q2 of FY25, down 11.93% YoY. On outlook front, the company stated, 'Advanced Enzymes is constantly working towards improving and strengthening its business model, and will continue to focus on all three divisions - Human Nutrition, Animal Nutrition and Bio-Processing including developing, adding and launching more products in the target market of probiotics. The company is confident that its existing capacities and capital investments would serve well to expand its enzymes and probiotics business.' Advanced Enzyme Technologies is a research driven company with global leadership in the manufacturing of enzymes and probiotics. The company provides eco-safe solutions to a wide variety of industries like human health care and nutrition, animal nutrition, baking, fruit & vegetable processing, brewing & malting, grain processing, protein modification, dairy processing, specialty applications, textile processing and others. Its aim is to replace traditionally used chemicals with eco-friendly enzymatic solutions. Powered by Capital Market - Live
5 months agoCapital Market - Live
Earnings
Advanced Enzyme Technologies consolidated net profit declines 4.59% in the September 2024 quarter
Net profit of Advanced Enzyme Technologies declined 4.59% to Rs 32.83 crore in the quarter ended September 2024 as against Rs 34.41 crore during the previous quarter ended September 2023. Sales declined 7.44% to Rs 146.10 crore in the quarter ended September 2024 as against Rs 157.84 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales146.10157.84 -7 OPM %29.0332.51 - PBDT51.1056.65 -10 PBT42.2147.93 -12 NP32.8334.41 -5 Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Advanced Enzyme Techs. announces board meeting date
Advanced Enzyme Techs. will hold a meeting of the Board of Directors of the Company on 9 November 2024Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Advanced Enzyme Techs. to table results
Advanced Enzyme Techs. will hold a meeting of the Board of Directors of the Company on 9 November 2024Powered by Capital Market - Live
5 months agoCapital Market - Live
Earnings
Advanced Enzyme Technologies consolidated net profit rises 18.54% in the June 2024 quarter
Net profit of Advanced Enzyme Technologies rose 18.54% to Rs 34.15 crore in the quarter ended June 2024 as against Rs 28.81 crore during the previous quarter ended June 2023. Sales rose 4.92% to Rs 154.52 crore in the quarter ended June 2024 as against Rs 147.28 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales154.52147.28 5 OPM %33.1229.89 - PBDT57.2950.04 14 PBT48.6741.41 18 NP34.1528.81 19 Powered by Capital Market - Live
8 months agoCapital Market - Live
Corporate
Advanced Enzyme Techs. announces board meeting date
Advanced Enzyme Techs. will hold a meeting of the Board of Directors of the Company on 10 August 2024.Powered by Capital Market - Live
8 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 9.24%, vs industry avg of 6.12%
Over the last 5 years, market share decreased from 0.76% to 0.75%
Over the last 5 years, net income has grown at a yearly rate of 3.72%, vs industry avg of -1.01%